Overview
BMY market data
Price History
BMY price chart
Valuation & Profitability
- P/E (TTM)
- 14.21 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.17 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.9% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 18.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $42.52 – $68.10 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $131.9B · P/B 5.94 · P/S 2.68.
Company News
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Aug 14, 2026, 8:30 PM
Bristol Myers Squibb Gets FDA Nod For Novel Multiple Myeloma TreatmentBenzinga · Aug 14, 2026, 4:07 PM
Bristol-Myers Squibb Receives FDA Approval For ZENBEXUS In Combination With Daratumumab And Hyaluronidase-fihj and Dexamethasone For Patients with Multiple MyelomaBenzinga · Aug 13, 2026, 9:20 PM
Cytokinetics Files Delaware U.S. District Court Claim Against Bristol-Myers Squibb And MyoKardia Seeking Judgment That CYTK Isn't Infringing U.S. Patent No. 12,616,697 And That The ’697 Patent Claims Are InvalidBenzinga · Aug 13, 2026, 1:35 PM
Atrium Therapeutics Announces $15M Milestone Payment From Bristol Myers Squibb On Delivery Of Second Lead Compound In Undisclosed Cardiology IndicationBenzinga · Aug 13, 2026, 12:05 PM
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’Benzinga · Aug 13, 2026, 8:33 AM
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'Benzinga · Aug 13, 2026, 2:41 AM
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga · Aug 11, 2026, 12:39 PM
Bristol Myers Squibb To Invest $2.3B In Houston Manufacturing Campus, Creating Nearly 500 JobsBenzinga · Aug 10, 2026, 1:04 PM
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer TreatmentBenzinga · Aug 7, 2026, 11:49 AM